mda-7 in Combination with Bevacizumab Treatment Produces a Synergistic and Complete Inhibitory Effect on Lung Tumor Xenograft
Abstract
Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has shown antitumor activity by inhibiting tumor angiogenesis in preclinical and clinical studies. However, bevacizumab monotherapy does not induce complete tumor regression. Therefore, additional treatments must be combined with bevacizumab to promote tumor regression. We previously showed that melanoma differentiation associated gene-7 (mda-7)...
Paper Details
Title
mda-7 in Combination with Bevacizumab Treatment Produces a Synergistic and Complete Inhibitory Effect on Lung Tumor Xenograft
Published Date
Feb 1, 2007
Journal
Volume
15
Issue
2
Pages
287 - 294
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History